| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
26,020,000 |
| Market
Cap: |
237.82(M) |
| Last
Volume: |
6,675 |
Avg
Vol: |
6,656 |
| 52
Week Range: |
$6.48 - $11.61 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Home Health Care |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of PEDMARK™ (sodium thiosulfate anhydrous injection) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Co. has licensed from Oregon Health & Science University intellectual property rights for the use of PEDMARK™ as a chemoprotectant and is developing PEDMARK™ as a protectant against the hearing loss caused by platinum-based anti-cancer agents in children.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
41,667 |
41,667 |
41,667 |
41,667 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
2 |
2 |
| Total Shares Sold |
382,252 |
442,611 |
479,045 |
530,118 |
| Total Sell Value |
$3,244,688 |
$3,814,302 |
$4,130,065 |
$4,620,238 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
17 |
23 |
30 |
37 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-17 |
4/A |
OE |
$2.31 |
$51,333 |
D/D |
22,222 |
22,222 |
|
- |
|
| Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-17 |
4 |
AS |
$9.91 |
$220,220 |
D/D |
(22,222) |
22,222 |
|
-4% |
|
| Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-17 |
4 |
S |
$2.31 |
$51,333 |
D/D |
(22,222) |
22,222 |
|
4% |
|
| Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-16 |
4/A |
OE |
$2.31 |
$51,333 |
D/D |
22,222 |
44,444 |
|
- |
|
| Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-16 |
4 |
AS |
$10.28 |
$228,389 |
D/D |
(22,222) |
0 |
|
-10% |
|
| Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-16 |
4 |
S |
$2.31 |
$51,333 |
D/D |
(22,222) |
44,444 |
|
10% |
|
| Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-15 |
4/A |
OE |
$2.31 |
$51,333 |
D/D |
22,222 |
22,222 |
|
- |
|
| Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-15 |
4 |
AS |
$10.30 |
$228,793 |
D/D |
(22,222) |
22,222 |
|
-11% |
|
| Haigh Adrian |
CHIEF OPERATING OFFICER |
• – – |
2024-04-15 |
4 |
S |
$2.31 |
$51,333 |
D/D |
(22,222) |
22,222 |
|
11% |
|
| Rallis Chris A |
|
– • – |
2024-04-15 |
4 |
OE |
$10.45 |
$14,515 |
D/D |
1,389 |
45,838 |
|
- |
|
| Rallis Chris A |
|
– • – |
2024-04-15 |
4 |
AS |
$10.45 |
$8,360 |
D/D |
(800) |
44,449 |
|
-11% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-05 |
4 |
AS |
$10.75 |
$476,269 |
D/D |
(44,300) |
187,471 |
|
-14% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-04 |
4 |
AS |
$10.89 |
$482,400 |
D/D |
(44,283) |
231,771 |
|
-16% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-03 |
4 |
AS |
$10.78 |
$437,451 |
D/D |
(40,584) |
276,054 |
|
-14% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-01 |
4 |
B |
$0.00 |
$0 |
D/D |
29,167 |
316,638 |
0.01 |
-15% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-01 |
4 |
B |
$0.00 |
$0 |
D/D |
12,500 |
104,271 |
0.01 |
-15% |
|
| Rallis Chris A |
|
– • – |
2024-03-26 |
4 |
OE |
$2.31 |
$10,000 |
D/D |
4,329 |
45,249 |
|
- |
|
| Rallis Chris A |
|
– • – |
2024-03-26 |
4 |
AS |
$10.97 |
$23,191 |
D/D |
(2,114) |
40,920 |
|
-15% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2024-03-26 |
4 |
AS |
$10.90 |
$152,346 |
D/D |
(13,975) |
91,771 |
|
-15% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2024-03-25 |
4 |
AS |
$11.00 |
$153,690 |
D/D |
(13,975) |
105,746 |
|
-16% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-05 |
4 |
AS |
$10.41 |
$156,150 |
D/D |
(15,000) |
119,721 |
|
-11% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-04 |
4 |
AS |
$10.64 |
$159,600 |
D/D |
(15,000) |
134,721 |
|
-14% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-12-28 |
4 |
S |
$11.55 |
$42,227 |
D/D |
(3,656) |
287,471 |
|
21% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-12-28 |
4 |
OE |
$1.59 |
$13,579 |
D/D |
8,540 |
291,127 |
|
- |
|
| Rallis Chris A |
Director |
– • – |
2023-12-26 |
4 |
OE |
$1.59 |
$4,999 |
D/D |
3,144 |
46,178 |
|
- |
|
56 Records found
|
|
Page 1 of 3 |
|
|
0.07 (0.76%) 
